Preoperative mapping of metastatic lesions in the liver is of crucial importance when patients are considered for surgical treatment. Computer tomography (CT) and intraoperative ultrasonography (IOUS) are most frequently used. Historically, CT missed approximately 20--40% of the malignant lesions compared with IOUS. The influence of IOUS on surgical decision making for hepatic malignancies has been documented by numerous reports since the 1980 s. The preoperatively planned surgical procedures were changed as a result of IOUS in 19--65% of cases \[[@CR1]--[@CR4]\].

CT scanning techniques (as well as ultrasonographic technology) have changed dramatically since then. The accuracy of modern imaging with high-resolution helical CT scanners has increased. However, the exact role of these techniques for the analysis of liver metastasis and for surgical decision making remains unclear.

The goal of this study was to determine the accuracy of preoperative CT scanning compared with IOUS in patients who were treated surgically for colorectal liver metastasis. The preoperative surgical plan was compared with the final surgical treatment to see whether intraoperative findings (IOUS and surgical exploration) affected the treatment strategy in our patient population.

Methods {#Sec1}
=======

One hundred consecutive patients who underwent surgery for colorectal liver metastases were included. All patients underwent preoperative helical CT imaging. Patients who are described in this series were for a large part also included in a Dutch national study in which patients were randomized between workup and follow-up with or without FDG-PET. Therefore, not all patients were analyzed with FDG-PET scanning.

In almost all patients referred to our institution, metastatic lesions were identified or suspicion was raised based on (periodic screening) transabdominal ultrasonography of the liver and/or an increase of serum CEA levels.

Routine preoperative 4-phase helical CT scans of the upper abdomen were obtained on a 4-slice multi-detector CT scanner (Somatom Volume Zoom, Siemens, Erlangen, Germany) or a 64-slice multi-detector CT scanner (Somatom Sensation, Siemens). The series were acquired at maximum inspiration before (unenhanced phase) and 30 seconds (hepatic arterial phase), 70 seconds (portal venous phase), and 300 seconds (equilibrium) after intravenous injection (3--4 ml/s) of 100 ml of a low-osmolar, nonionic contrast agent with an iodine concentration of 300 mg/ml (Ultravist-300 Iopromide; Bayer Pharma AG, Berlin, Germany), using an injection pump through an 18-g cannula in the left or right antecubital vein. Scanning parameters were 120 kV and 180 mAs with dose modulation at a slice collimation of 4 x 2.5, rotation time of 0.5 seconds, and pitch of 1.25 for the 4-slice multi-detector CT scanner, and collimation of 32 x 0.6 mm, rotation time of 0.33 seconds, and pitch of 0.75 for the 64-slice multi-detector CT. All series were reconstructed in 5-mm contiguous axial and coronal slices.

In our hospital, 4-phase CT of the upper abdomen was routinely performed for all patients who had no recent CT scan (acquired maximum 4 weeks before surgery) and for all atypical liver lesions on recent portal-venous-phase-only scans from other hospitals (such as hypervascular or cystic-appearing liver metastases). If necessary, gadolinium-enhanced liver magnetic resonance imaging (MRI) was used as a problem solver. Several patients already underwent a preoperative CT scan at an outside institution. All of these images were reviewed by our radiologists and if needed additional scans were made.

All patients underwent IOUS (Prosound Alpha10; 10.0-MHz linear intraoperative probe and 5.0/1.25-MHz convex probe, Aloka, Tokyo, Japan) performed by an experienced interventional radiologist, who carefully noted the exact size (maximum diameter), number, and location of all CRLM.

The intraoperative findings were saved. Data recorded included the number and size of hepatic malignant lesions and evidence of local extension of disease. The findings on preoperative and intraoperative imaging and surgical exploration were compared regarding number and extension of the hepatic lesions. To assess whether treatment was altered, all surgeons' reports were reviewed and evaluated. Ultimately, the surgical treatment strategy resection---radiofrequency ablation (RFA) alone or combined with resection---was based on the intraoperative findings.

Results {#Sec2}
=======

Between January 2007 and January 2009, 100 consecutive patients (55 men, 45 women) with CRLM underwent 117 surgical procedures, resection, RFA, or a combination of both. The characteristics of the patients and their primary tumors are summarized in Table [1](#Tab1){ref-type="table"}. The surgical treatment methods are summarized in Table [2](#Tab2){ref-type="table"}.Table 1Characteristics of patients and localization of primary carcinomasCharacteristicDataTotal no. patients100Male/female ratio55/45Age (yr) Median65 Range37--82Primary tumor Colon68 Rectosigmoid11 Rectum21Table 2Summary of 117 surgical treatments of hepatic metastases in 100 patientsSurgical treatmentFrequency (%)Hemihepatectomy23 (20%) Left12 (10%) Right9 (8%) Extended2 (2%)Partial resection^a^46 (39%)RFA alone30 (26%)Combined treatment^b^13 (11%) RFA and resection11 (9%) RFA and right portal vein ligation 2 (2%)None^c^5 (4%)Total117 (100%)^a^Partial resection comprises metastasectomies and segmentectomies^b^RFA and right portal ligation was combined in two patients with bilobar liver metastases to achieve hypertrophy of the left liver segments, making a secondary hemihepatectomy possible. In one patient, portal vein ligation alone was attempted to achieve the same, but this patient developed extrahepatic metastatic disease^c^No surgical treatment was undertaken in five patients because of diffuse intrahepatic metastases in three and peritoneal carcinomatosis in two patients. However, one patient with diffuse metastases underwent combined RFA and resection of his bilobar metastases 7 months after his explorative laparotomy and chemotherapy treatment

Overall, intraoperative findings (IOUS plus surgical exploration) yielded additional information on number, size, localization, and/or local extension of metastases in 45 cases (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Concordance between pre- and intraoperative

In 38 of the patients, findings on IOUS differed from those of the preoperative CT scan. In 23 of those cases, IOUS identified more hepatic malignant lesions than the preoperative CT scan: 20 true new lesions, and 3 satellite lesions originating from known metastases. In four patients, IOUS detected fewer lesions. In one patient, the metastatic lesion was smaller on IOUS than anticipated on the preoperative CT scan, changing the surgical treatment to a less extensive resection.

Additional information on the localization of the hepatic lesions was gathered by IOUS and changed the surgical treatment in ten cases. This additional information led to more extensive resection in two cases. In seven patients, a RFA procedure was performed instead or additionally. In one patient, the hepatic lesion was found to be located more superficial than expected, changing the preoperative plan to perform a RFA procedure into a wedge resection.

Cohen's kappa measure of concordance between CT and IOUS findings was 0.84 for the number of CRLM and 0.79 for number, exact size, and localization of CRLM.

Surgical exploration identified more extensive extrahepatic disease in seven patients. In four patients, exploration detected diaphragmatic invasion, which altered the treatment; partial diaphragmatic resection was performed en bloc with the liver metastasis.

In three patients, surgical exploration identified peritoneal metastatic deposits. In two of these patients, the metastatic deposits were so extensive that resection was not possible. However, the other patient had only limited extrahepatic disease (solitary peritoneal deposits), amenable for resection.

Intraoperative findings (IOUS plus surgical exploration) changed the preoperative surgical plan for 42 of 117 procedures. In 45 patients, the intraoperative findings differed from the information gathered preoperatively on CT; in only three patients, these discrepancies did not result in a change of treatment strategy.

IOUS alone altered the surgical strategy 35 times during 117 treatments (30%). In nearly all (92%) cases, discrepancy between the preoperative CT scan and IOUS resulted in a change of surgical treatment. In general, IOUS identified more hepatic metastases, necessitating more extensive hepatic resection, RFA instead of resection, or a combination of those treatment modalities.

No surgical treatment was undertaken initially for an additional three patients because of diffuse intrahepatic metastases. However, one of the patients with diffuse metastases underwent combined treatment of RFA and resection 7 months after successful downstaging with chemotherapy.

Discussion {#Sec3}
==========

Intraoperative ultrasonography has been considered the "gold standard" since it was shown that the additional information found for many patients had a great impact on the surgical plan. Various authors reported that IOUS provided new information that influenced surgery in up to 50% of cases \[[@CR1]--[@CR4]\]. With the availability of modern imaging techniques, some have questioned the need for IOUS as diagnostic tool and only use it to plan their resection \[[@CR5], [@CR6]\].

In our series, however, the importance of IOUS in detecting preoperatively unknown lesions remains high. In 38% of patients, IOUS differed from the preoperative CT scan; more importantly, if discrepancies were found between IOUS and CT it nearly always changed the type of resection that was performed. These results are confirmed by others. Even though Ellsmere et al. questioned, "Why are we still performing IOUS during planned liver resection," they found that the frequency of unrecognized tumors during surgery did not change during the past 10 years. They compared 50 consecutive cases with a comparable historical group. They found that the rate of undetected tumors ranged between 14--20%, changing their surgical plan in one fifth of patients \[[@CR5]\].

In resent years not only the CT scan has been used for the preoperative workup. FDG-PET is of great importance in staging colorectal liver metastases, but whether FDG-PET changes the "gold standard" of IOUS remains to be seen. Patients described in this series were for a large part also included in a Dutch national study in which patients were randomized between workup and follow-up with or without FDG-PET. As a result, half of the patients were analyzed and operated without preoperative PET scan. Therefore, we could not use these data in this analysis. The results of this study were presented recently and showed that workup with FDG-PET reduced the number of futile laparotomies; however, it did not influence disease-free survival or the total costs. The complete results will be published in the near future. Wiering et al. analyzed the accuracy of CT and FDG-PET compared with IOUS. Both PET and CT were sensitive for detecting lesions \>2 cm. However, sensitivity declined rapidly when lesions were \<2 cm. Only 16% of lesions \<1 cm were detected preoperatively \[[@CR7]\]. The results of this study are comparable with our data that 30% more lesions were found during laparotomy. Strangely, this difference with preoperative knowledge had hardly any influence on clinical management. Previous studies from this group did show that FDG-PET decreased the number of futile laparotomies by better detection of extrahepatic disease \[[@CR8], [@CR9]\].

Wildi et al. studied preoperative PET/CT with or without IOUS and correlated these results with histopathological and clinical follow-up data. They found that sensitivity of PET/CT alone was 63% versus 93% when PET/CT was combined with IOUS. After preoperative chemotherapy, these data were comparable: PET/CT 77% and combined with IOUS 100%. In 35% of the cases, IOUS changed the surgical plan \[[@CR10]\].

Rohren et al. also studied the importance of FDG-PET and compared this with IOUS. They found that FDG-PET is highly accurate in determining the presence or absence of hepatic metastases; however, FDG-PET is less accurate in determining the precise number and distribution of hepatic metastases. FDG-PET accurately defined the number and location on lesions in 55% of patients. As in other studies, lesion size was a significant factor in the detection of hepatic metastases by FDG-PET. Whether the preoperative plan based on PET changed due to intraoperative finding was not discussed \[[@CR11]\].

In contrast with these data are the resent results of Figueras et al., which report a low sensitivity of CT scan alone; however, IOUS only changed their surgical procedure in 11% \[[@CR12]\]. Overall, the conclusion can be made that IOUS remains the "gold standard" for the number and location of liver metastases. PET/CT is simply not sensitive enough to detect smaller lesions.

In our clinic, we hold the policy to spare as much liver parenchyma as possible---of course never at the cost of irradicality. There are two reasons for this policy. First, it reduces the need for major hepatectomies, which are associated with morbidity and mortality. Second, it makes secondary surgery for recurrent disease easier. IOUS helps us plan our resections. The varying results of whether IOUS changes the surgical plan depend, of course, mainly on the extent of the planned resection \[[@CR13]\]. If you are sparing liver volume, it will change your surgical plan.

Even though IOUS can currently be considered the best there is, it is obviously not good enough. Almost half of the patients will have recurrent disease in the liver; most of these lesions develop out of small metastases present during the first exploration and therefore were missed by IOUS.

Various imaging techniques are analyzed to see whether preoperative accuracy can be improved.

Recently, we published the preliminary results of total-liver-volume perfusion CT (CTP) technique for the detection and characterization of liver metastases \[[@CR14]\]. Twenty patients underwent helical CT of the total liver volume before and 11 times after intravenous contrast-material injection. To decrease distortion artefacts, all phases were coregistered using 3-D image fusion before creating blood-flow maps. Lesion-based sensitivity and specificity for liver metastases of first the conventional 4 phases and later all 12 phases, including blood-flow maps, were determined compared to intraoperative ultrasound and surgical exploration. These preliminary results showed significantly increased sensitivity of total-liver-volume CTP.

Currently, we also are using contrast-enhanced intraoperative ultrasound (CE-IOUS) to improve the results; however, it is too early to report our data.

Leen et al. recently showed that CE-IOUS was significantly more sensitive than IOUS (96.1% versus 81.5%) \[[@CR15]\]. It altered their surgical management in almost 30% of cases. However, in this study there was no difference between preoperative imaging and conventional IOUS, which is somewhat surprising considering the current literature. Furthermore, the median size of the additional lesions found with CE-IOUS was 8 mm, which is well over the detection limit of conventional IOUS. Even though the improved sensitivity of contrast-enhanced ultrasound is confirmed in some studies, others question its value \[[@CR16], [@CR17]\].

The current results of gadolinium-enhanced MRI for colorectal liver metastases are still under debate; however, sensitivity and specificity seems slightly higher compared with portal-venous-phase contrast-enhanced helical CT \[[@CR18]\].

In conclusion, despite improvement of preoperative imaging technology, the intraoperative use of ultrasonography remains crucially important. The detection of preoperatively unknown lesions is high with great consequence on surgical therapy. New techniques, such as total-liver-volume perfusion CT and contrast-enhanced intraoperative ultrasound and MRI, are being studied to improve diagnostic accuracy of preoperative imaging.
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